Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease.
about
Smallpox vaccines for biodefense: need and feasibilityMultiple viral ligands naturally presented by different class I molecules in transporter antigen processing-deficient vaccinia virus-infected cellsUse of licensed vaccines for active immunization of the immunocompromised hostAn orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus ChallengePoxvirus vectors as HIV/AIDS vaccines in humansCritical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpoxInternational travel and HIV infectionImmunizations for foreign travelEfficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for treatment of vaccinia virus (orthopoxvirus) infections in miceHuman poxvirus infection after the eradication of smallpoxEstimating the Size of the U.S. Population at Risk of Severe Adverse Events from Replicating Smallpox Vaccine.Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes.Current issues in the development of a vaccine to prevent human immunodeficiency virus: insights from the society of infectious diseases pharmacists.High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine.High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults.New generation smallpox vaccines: a review of preclinical and clinical data.Diversity in the acute CD8 T cell response to vaccinia virus in humans.Diminished intracellular invariant chain expression after vaccinia virus infection.Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challengeComparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIVHuman parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicityHighly attenuated vaccinia virus mutants for the generation of safe recombinant virusesIndividual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccinationImmunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults.Activation of the human immunodeficiency virus type 1 long terminal repeat by vaccinia virus.Unpolarized release of vaccinia virus and HIV antigen by colchicine treatment enhances intranasal HIV antigen expression and mucosal humoral responses.Efficacy of cidofovir in a murine model of disseminated progressive vaccinia.Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus AnkaraProtection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccinePostexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulinVaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes.Strategies for an HIV vaccine.Smallpox vaccine safety is dependent on T cells and not B cellsLong-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults.Vaccine-induced protection against orthopoxvirus infection is mediated through the combined functions of CD4 T cell-dependent antibody and CD8 T cell responses.Vaccines for Category A bioterrorism diseases.
P2860
Q22305942-3BF22FF7-1BB9-4E5A-9461-031DDB7099A2Q24294775-136E4C65-82CC-4C9F-8BDD-78833A26E919Q24533456-86AF5B7A-E52A-420E-BC3A-D51D52B43CB7Q24535956-051B8922-B20E-4F3E-9A6B-88AAFC94697EQ26995078-493C6D59-3C75-420A-865A-498E5BF6CA46Q27346933-B0CA526E-5904-40D1-AC81-2A4AF1C0BCDCQ27486095-AEE3B800-AACD-416D-BF2B-543729D7C5BFQ27487373-929895A8-62FE-4B3E-A3A3-4143EDDF4490Q28345238-B9709891-5FCD-48F7-B04E-A3E4673F9CFAQ28767649-B7605945-86B3-4800-BF9A-EB121425E007Q30151714-86E547DB-A968-4C67-A782-D9CDA7F819C7Q30339052-04120078-2061-4EC4-9EFE-34DD1309922AQ30350731-B5DD3695-36C9-4487-99FE-CFEA43E8B701Q30362521-1AE606F4-A86D-4257-92D2-438B9812764BQ30412595-A6D31DBD-0138-41A4-805F-9A4B430EED6AQ31147081-B5DB9F4E-E83D-4AA7-8A9D-D6386212C0BCQ33227607-E8285518-3041-4181-A560-E175DB33D443Q33747640-7869CFFC-AAA3-4564-A438-C95FE5CCB2EDQ33780579-E1150E5F-FA4B-4A65-965C-9E6BD2BBB279Q33784928-257C154C-6BDF-4BC3-B678-19A8853F8681Q33799497-E5F4488B-D7A0-4579-9621-A3BF60224423Q33800033-9EC2D66B-A65E-4D53-9BC3-1F3A62A4F40DQ33808578-B74B0EE7-9EBA-4A1B-9938-27B8075A0A16Q33834391-A0994273-B0F0-4F65-ABFF-DF633650E9BAQ33838030-4D346AC4-4B15-4E8B-B26C-48E0565616D3Q33850032-A3D8CAD5-3FDE-4390-AA35-977987A5C813Q33851802-4525FC22-3B89-4151-B204-69B692348F69Q33879545-7C982EE0-801A-4327-B38E-AD4E61FBC1D2Q33930958-A8DDE2A5-732E-40C1-85D0-51B1D70E345AQ34026061-B93049BB-7034-496C-A234-3D8A354427D3Q34140816-38391301-AED1-4D96-9403-7412AD1130A4Q34343169-5435D635-4701-4674-AE26-E1432977BA0AQ34431934-D299B921-4A9B-4AC8-AFEB-3DB3CE0D04B5Q34484027-8ED9D8DF-0CA0-445B-B723-F5A515D8720FQ34714569-676DFBFC-0F41-46CC-8E42-D92E862823B5Q34717847-92B4D933-5708-45A1-958D-DDF46C12EF8CQ34743303-43CCC0FB-2B8C-4E81-8669-A021E25939A5Q34775950-233E7DED-DA9C-47FC-AA21-5DD8756DB7F8Q34991389-C23D10BE-5BDD-4183-9286-141ECB0ECD5DQ35040844-9D204333-8BA7-4D15-B12B-45097DADFFDA
P2860
Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Disseminated vaccinia in a mil ...... eficiency virus (HIV) disease.
@en
Disseminated vaccinia in a military recruit with human immunodeficiency virus
@nl
type
label
Disseminated vaccinia in a mil ...... eficiency virus (HIV) disease.
@en
Disseminated vaccinia in a military recruit with human immunodeficiency virus
@nl
prefLabel
Disseminated vaccinia in a mil ...... eficiency virus (HIV) disease.
@en
Disseminated vaccinia in a military recruit with human immunodeficiency virus
@nl
P2093
P1476
Disseminated vaccinia in a mil ...... eficiency virus (HIV) disease.
@en
P2093
P304
P356
10.1056/NEJM198703123161106
P407
P577
1987-03-01T00:00:00Z